Wild swings hit the ASX this week, with Janus Electric doubling, Aura sliding almost 30%, and TechGen jumping more than 22%. Big news kept landing, but many stocks still fell as early gains faded and traders locked in profits.
- Janus Electric was the week’s biggest mover, surging 100% after a new US truck conversion order.
- Aura fell 29.58% even after completing the Qoria deal and raising fresh capital.
- Gold M&A took centre stage as Genesis and Vault agreed to merge into a A$12.6 billion producer.
- Resources news stayed busy, with strong drill results and resource upgrades across copper, gold, tungsten and rare earths.
- Several healthcare names rose on commercial deals, approvals and trial progress.
Janus Electric (ASX:JNS) led the week’s biggest moves with a 100.00% jump after locking in a A$10 million US order that lifted its North American book to 45 truck conversions. Aura Consolidated Group (ASX:AXQ) went the other way, dropping 29.58% even as it completed the Qoria acquisition and raised US$100 million. TechGen Metals (ASX:TG1) climbed 22.73% after extending its Red Devil copper-gold zone to 1.8km ahead of first drilling. Those moves set the tone for a week where fresh announcements moved prices fast, but not always in the expected direction.
Gold gets bigger
Genesis Minerals (ASX:GMD) and Vault Minerals (ASX:VAU) agreed to merge in a deal that would create a top-three Australian gold producer worth about A$12.66 billion. Vault holders are set to receive Genesis shares plus cash, and the companies say the combined group could save about A$2 billion over 10 years. Investors cared because bigger gold groups can often cut duplicate costs and make better use of nearby plants and mines. Even so, both stocks fell for the week, with Vault down 5.13% and Genesis off 1.94%, which suggests some traders sold into the news rather than chase it. Elsewhere in gold, Brightstar Resources (ASX:BTR) stayed active after securing full funding for its Goldfields build and lifting Sandstone resources to 2.9 million ounces. Ora Banda Mining (ASX:OBM) also delivered two strong updates: a 75% lift in resources, a 159% jump in reserves, and record FY26 gold output. Yet Ora Banda still fell 10.71% for the week. That tells a simple story. Good operating news was not enough to stop profit-taking after a busy run.Drill hits still move small caps
Copper and gold explorers filled the winners list. White Cliff Minerals (ASX:WCN) rose 6.25% after hitting more than 90 metres of copper sulphides at Rae and raising A$6.5 million for more drilling. Kingfisher Mining (ASX:KFM) gained 5.26% on strong copper-gold assays at Copper Blow. Hammer Metals (ASX:HMX) added 1.59% after a 165-metre copper equivalent hit at Kalman. In plain English, investors saw thicker mineralised zones and a better chance that future mining studies could work. Not every explorer held its gains. Sky Metals (ASX:SKY) unveiled a larger Tallebung resource and a maiden silver addition, but still finished down 11.54%. Brazilian Rare Earths (ASX:BRE) fell 11.25% despite high-grade yttrium-rich rare earth results. In several of these names, early buying after a halt gave way to selling later in the week. That usually means traders liked the news, but not enough to keep paying higher prices.Healthcare names find buyers
Medical and biotech stocks had a steadier run. Cyclopharm (ASX:CYC) rose 14.29% after winning an 11-site Technegas rollout with University Hospitals Cleveland. EMVision (ASX:EMV) gained 8.00% as its brain scanner trial passed enrolment milestones and held A$17.1 million in cash. Microba Life Sciences (ASX:MAP) added 7.32% after reporting 92% growth in core testing revenue and setting a September launch for GI Navigator. CLINUVEL Pharmaceuticals (ASX:CUV) slipped 3.41% even after winning Canadian approval for SCENESSE. Starpharma (ASX:SPL) edged down 0.84% after launching a A$32 million entitlement offer. New money raisings often pressure prices in the short term because new shares are sold at a discount, which gives buyers a cheaper entry point.Big producers stayed firm, but not immune
The largest miners delivered solid operating updates. BHP (ASX:BHP) posted record iron ore production and stable copper output, though the stock still eased 1.27%. Rio Tinto (ASX:RIO) reported 3% copper equivalent production growth for the first half, led by Oyu Tolgoi and strong Pilbara iron ore volumes, yet closed down 2.15%. Evolution Mining (ASX:EVN) met production targets and delivered record cash flow, but fell 9.46%. Away from mining, financial platform operator Netwealth (ASX:NWL) held up relatively well, down just 1.59% after reporting record funds under administration of A$135.7 billion. Australian Finance Group (ASX:AFG) slipped 3.01% despite record home loan lodgements. Investors appear to be rewarding growth, but they are still quick to sell if a stock has already had a strong run or if broader sentiment turns cautious.Why good news still met selling
A clear pattern ran through the week. Many companies posted strong updates on drilling, funding, production or contracts, but their share prices still fell. Sometimes the reason was simple: the stock had already run hard before the announcement. In other cases, a trading halt ended, buyers rushed in, then those early gains evaporated as sellers took cash off the table. That was visible across several small-cap resource names and in some capital raisings. For newer investors, this matters. A good company update does not guarantee a higher closing price. Traders also ask whether the stock was already expensive, whether new shares are being issued cheaply, and whether the next step still carries risk. If drilling must still prove scale, or if a mine or product launch is years away, some buyers will wait rather than chase the first move.Bottom Line?
Next week’s attention is likely to stay on deal completion steps for Genesis and Vault, further drilling news from active explorers, and upcoming results dates such as Aura’s Q2 2026 earnings on 6 August and audited results from Skellerup on 20 August.
Questions in the middle?
- Will the Genesis-Vault merger win shareholder support quickly, or will investors push back on the terms and expected synergies?
- Can small-cap explorers turn strong drill results into resource upgrades fast enough to keep buyers engaged?
- Will recent healthcare winners convert approvals, trial progress and rollout deals into meaningful revenue growth over the next few quarters?